AstraZeneca's Tozorakimab Surpasses Expectations in Lung Disease Trials, Boosting Stock 4%.

AstraZeneca's stock has jumped 4% after the company announced that its experimental lung disease drug Tozorakimab met its target in two late-stage clinical trials. The drug reduced flare-ups of chronic obstructive pulmonary disease in both former smokers and the overall population compared to placebo. The treatment works by suppressing the action of interleukin-33 (IL-33) and can reduce inflammation.